دورية أكاديمية
أعرض في EDS

A novel myelin protein zero transgenic zebrafish designed for rapid readout of in vivo myelination.

التفاصيل البيبلوغرافية
العنوان: A novel myelin protein zero transgenic zebrafish designed for rapid readout of in vivo myelination.
المؤلفون: Preston MA; Department of Cell and Developmental Biology, University of Colorado School of Medicine, Aurora, Colorado., Finseth LT; Department of Cell and Developmental Biology, University of Colorado School of Medicine, Aurora, Colorado., Bourne JN; Department of Cell and Developmental Biology, University of Colorado School of Medicine, Aurora, Colorado., Macklin WB; Department of Cell and Developmental Biology, University of Colorado School of Medicine, Aurora, Colorado.
المصدر: Glia [Glia] 2019 Apr; Vol. 67 (4), pp. 650-667. Date of Electronic Publication: 2019 Jan 09.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8806785 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-1136 (Electronic) Linking ISSN: 08941491 NLM ISO Abbreviation: Glia Subsets: MEDLINE
أسماء مطبوعة: Publication: New York, NY : Wiley-Liss
Original Publication: New York : Alan R. Liss, Inc., c1988-
مواضيع طبية MeSH: Demyelinating Diseases/*genetics , Gene Expression Regulation, Developmental/*genetics , Green Fluorescent Proteins/*metabolism , Myelin P0 Protein/*metabolism , Myelin Sheath/*physiology, Animals ; Animals, Genetically Modified ; Culture Media, Conditioned/pharmacology ; Demyelinating Diseases/metabolism ; Demyelinating Diseases/pathology ; Disease Models, Animal ; Embryo, Nonmammalian ; Embryonic Stem Cells ; Gene Expression Regulation, Developmental/drug effects ; Green Fluorescent Proteins/genetics ; Immunosuppressive Agents/pharmacology ; Larva ; Luminescent Proteins/genetics ; Luminescent Proteins/metabolism ; Myelin Basic Protein/genetics ; Myelin Basic Protein/metabolism ; Myelin P0 Protein/genetics ; Myelin Sheath/ultrastructure ; Neuroglia/metabolism ; Oligodendroglia/drug effects ; Oligodendroglia/physiology ; SOXE Transcription Factors/genetics ; SOXE Transcription Factors/metabolism ; Sirolimus/pharmacology ; Spinal Cord/embryology ; Spinal Cord/metabolism ; Zebrafish ; Zebrafish Proteins/genetics ; Zebrafish Proteins/metabolism ; Red Fluorescent Protein
مستخلص: Demyelination occurs following many neurological insults, most notably in multiple sclerosis (MS). Therapeutics that promote remyelination could slow the neurological decline associated with chronic demyelination; however, in vivo testing of candidate small molecule drugs and signaling cascades known to impact myelination is expensive and labor intensive. Here, we describe the development of a novel zebrafish line which uses the putative promoter of Myelin Protein Zero (mpz), a major structural protein in myelin, to drive expression of Enhanced Green Fluorescent Protein (mEGFP) specifically in the processes and nascent internodes of myelinating glia. We observe that changes in fluorescence intensity in Tg(mpz:mEGFP) larvae are a reliable surrogate for changes in myelin membrane production per se in live larvae following bath application of drugs. These changes in fluorescence are strongly predictive of changes in myelin-specific mRNAs [mpz, 36K and myelin basic protein (mbp)] and protein production (Mbp). Finally, we observe that certain drugs alter nascent internode number and length, impacting the overall amount of myelin membrane synthesized and a number of axons myelinated without significantly changing the number of myelinating oligodendrocytes. These studies demonstrate that the Tg(mpz:mEGFP) reporter line responds effectively to positive and negative small molecule regulators of myelination, and could be useful for identifying candidate drugs that specifically target myelin membrane production in vivo. Combined with high throughput cell-based screening of large chemical libraries and automated imaging systems, this transgenic line is useful for rapid large scale whole animal screening to identify novel myelinating small molecule compounds in vivo.
(© 2019 Wiley Periodicals, Inc.)
References: J Neurosci. 2000 Jul 15;20(14):5225-33. (PMID: 10884306)
Curr Opin Neurol. 2001 Jun;14(3):271-8. (PMID: 11371748)
Dev Dyn. 2001 Sep;222(1):40-51. (PMID: 11507768)
Neuroreport. 2002 May 24;13(7):923-8. (PMID: 12004191)
Glia. 2002 Jul;39(1):47-57. (PMID: 12112375)
Dev Biol. 2002 Aug 15;248(2):356-68. (PMID: 12167410)
Nat Rev Neurosci. 2002 Sep;3(9):705-14. (PMID: 12209119)
Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12651-6. (PMID: 12271129)
Glia. 2003 Feb;41(3):301-17. (PMID: 12528184)
J Neuropathol Exp Neurol. 2003 Jan;62(1):25-33. (PMID: 12528815)
Nat Genet. 2003 Mar;33(3):366-74. (PMID: 12590258)
Genome Res. 2003 Mar;13(3):476-84. (PMID: 12618378)
Prog Neurobiol. 2003 Sep;71(1):49-56. (PMID: 14611867)
Glia. 2004 Mar;45(4):378-91. (PMID: 14966869)
Neurology. 2004 Dec 28;63(12 Suppl 6):S3-7. (PMID: 15623668)
Glia. 2005 Apr 1;50(1):86-90. (PMID: 15657937)
Invest Ophthalmol Vis Sci. 2005 Aug;46(8):2716-25. (PMID: 16043843)
J Neuroimmunol. 2006 Jul;176(1-2):162-73. (PMID: 16753227)
Brain Pathol. 2006 Apr;16(2):99-109. (PMID: 16768749)
Nat Protoc. 2006;1(2):960-7. (PMID: 17406330)
CNS Drug Rev. 2007 Spring;13(1):79-95. (PMID: 17461891)
Dev Dyn. 2007 Nov;236(11):3088-99. (PMID: 17937395)
Dev Dyn. 2007 Dec;236(12):3402-7. (PMID: 17969181)
Trends Neurosci. 2008 Jan;31(1):44-52. (PMID: 18063497)
Cell Stem Cell. 2008 Feb 7;2(2):183-9. (PMID: 18371439)
Zebrafish. 2008 Summer;5(2):97-110. (PMID: 18554173)
Annu Rev Neurosci. 2008;31:247-69. (PMID: 18558855)
Nat Protoc. 2008;3(8):1318-27. (PMID: 18714300)
Nat Rev Neurosci. 2008 Nov;9(11):839-55. (PMID: 18931697)
Yeast. 2009 Sep;26(9):497-505. (PMID: 19621470)
Neuron Glia Biol. 2008 May;4(2):71-81. (PMID: 19737431)
Curr Opin Neurobiol. 2009 Oct;19(5):486-90. (PMID: 19740648)
Dev Dyn. 2010 Feb;239(2):592-7. (PMID: 19918882)
Exp Neurol. 2010 Sep;225(1):18-23. (PMID: 20044992)
Glia. 2010 May;58(7):802-12. (PMID: 20140960)
Glia. 2010 Jun;58(8):996-1006. (PMID: 20229602)
J Neurosci. 2010 Mar 31;30(13):4693-706. (PMID: 20357120)
J Neuroimmunol. 2011 Jun;235(1-2):9-17. (PMID: 21402415)
Neurotherapeutics. 2011 Apr;8(2):262-73. (PMID: 21404073)
J Comp Neurol. 2011 Jun 1;519(8):1580-96. (PMID: 21452240)
Front Biosci (Schol Ed). 2011 Jun 01;3:1165-79. (PMID: 21622263)
Development. 2011 Oct;138(19):4327-32. (PMID: 21865323)
Development. 2011 Oct;138(20):4443-50. (PMID: 21880787)
Methods Cell Biol. 2011;105:25-62. (PMID: 21951525)
PLoS One. 2012;7(1):e29916. (PMID: 22238673)
J Pharmacol Exp Ther. 2012 Apr;341(1):274-84. (PMID: 22267202)
Nature. 2012 Apr 29;485(7399):517-21. (PMID: 22622581)
Nature. 2012 Jul 26;487(7408):443-8. (PMID: 22801498)
Ann Neurol. 2012 Dec;72(6):918-26. (PMID: 23076662)
Neural Dev. 2012 Nov 05;7:35. (PMID: 23122226)
J Neurol Sci. 2013 May 15;328(1-2):9-18. (PMID: 23518370)
Dev Cell. 2013 Jun 24;25(6):599-609. (PMID: 23806617)
Interface Focus. 2013 Jun 6;3(3):20130001. (PMID: 23853708)
Front Cell Neurosci. 2013 Sep 27;7:169. (PMID: 24098271)
Exp Neurol. 2014 Jan;251:39-46. (PMID: 24200549)
Toxicol Appl Pharmacol. 2014 Jan 15;274(2):339-49. (PMID: 24262764)
Cell. 1987 Feb 27;48(4):703-12. (PMID: 2434242)
J Neurosci. 2014 Jan 22;34(4):1333-43. (PMID: 24453324)
Glia. 2014 Sep;62(9):1513-29. (PMID: 24863526)
Nat Med. 2014 Aug;20(8):954-960. (PMID: 24997607)
Dev Dyn. 2014 Dec;243(12):1511-23. (PMID: 25130183)
Glia. 2015 Feb;63(2):177-93. (PMID: 25263121)
J Biomol Screen. 2015 Mar;20(3):382-90. (PMID: 25394729)
Nat Neurosci. 2015 May;18(5):683-9. (PMID: 25849987)
Sci Rep. 2015 Jul 07;5:11771. (PMID: 26148899)
Neurosci Bull. 2015 Oct;31(5):617-25. (PMID: 26253956)
Nat Rev Drug Discov. 2015 Oct;14(10):721-31. (PMID: 26361349)
Genes Dev. 2015 Dec 1;29(23):2504-15. (PMID: 26584621)
PLoS One. 2015 Dec 10;10(12):e0144550. (PMID: 26658258)
J Steroid Biochem Mol Biol. 2016 Jun;160:43-52. (PMID: 26776441)
J Neurosci. 2016 Jan 20;36(3):957-62. (PMID: 26791223)
J Neurosci. 2016 Jul 20;36(29):7628-39. (PMID: 27445141)
BMC Res Notes. 2016 Sep 05;9(1):419. (PMID: 27592856)
Methods Cell Biol. 2017;138:383-414. (PMID: 28129853)
Sci Rep. 2017 Apr 07;7:45780. (PMID: 28387380)
Elife. 2017 Sep 07;6:. (PMID: 28880149)
Elife. 2018 Jul 06;7:. (PMID: 29979149)
Dev Dyn. 1995 Jul;203(3):253-310. (PMID: 8589427)
Annu Rev Immunol. 1996;14:483-510. (PMID: 8717522)
Mult Scler. 1997 Apr;3(2):84-7. (PMID: 9291159)
J Comp Neurol. 1998 May 18;394(4):506-19. (PMID: 9590558)
Science. 1998 Jun 5;280(5369):1610-3. (PMID: 9616125)
معلومات مُعتمدة: NS078386 United States NS NINDS NIH HHS; FG 2078-A-1 United Kingdom Multiple Sclerosis Society; FG 2078-A-1RG 5334-A-12 United Kingdom Multiple Sclerosis Society; R21 NS078386 United States NS NINDS NIH HHS; RG 5334-A-12 United Kingdom Multiple Sclerosis Society
فهرسة مساهمة: Keywords: in vivo; myelin protein zero; myelination; oligodendrocytes; zebrafish
المشرفين على المادة: 0 (Culture Media, Conditioned)
0 (Immunosuppressive Agents)
0 (Luminescent Proteins)
0 (Myelin Basic Protein)
0 (Myelin P0 Protein)
0 (SOXE Transcription Factors)
0 (Zebrafish Proteins)
0 (enhanced green fluorescent protein)
0 (sox10 protein, zebrafish)
147336-22-9 (Green Fluorescent Proteins)
W36ZG6FT64 (Sirolimus)
تواريخ الأحداث: Date Created: 20190110 Date Completed: 20190611 Latest Revision: 20231213
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC6555554
DOI: 10.1002/glia.23559
PMID: 30623975
قاعدة البيانات: MEDLINE
الوصف
تدمد:1098-1136
DOI:10.1002/glia.23559